Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05505864
Other study ID # 120585
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2022
Est. completion date September 2023

Study information

Verified date January 2023
Source Western University
Contact Harry Prapavessis, PhD
Phone 519 661-2111
Email hprapave@uwo.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this health behaviour change research study is to assist adults with T2D in achieving the Canadian 24-hour sedentary behaviour movement guidelines.


Description:

Adults with type 2 diabetes (T2D) are less active and accumulate more sedentary behaviour (SB) than those without. Among adults with T2D, increased SB is associated with increased mortality after adjusting for physical activity. Canadian 24-hour SB movement guidelines recommend limiting SB to ≤8 hours, no more than 3 hours of recreational screen time, and breaking up long periods of SB as often as possible. Therefore, the purpose of this research study is for adults with T2D to achieve these SB Canadian 24-hour SB movement guidelines. To address this purpose, we will be conducting a six-week two-arm repeated measures randomized control trial. The intervention group will receive a theory-based behaviour change counselling session through zoom at week 0, mobile phone application at weeks 2 and 4 that encourage participants to create their own personal and specific action plans and coping strategies, and daily text messages that motivate participants to reduce and break up their SB. The control group will receive no intervention. The primary objective of the study is to reduce SB, while the secondary objectives are to break up SB, reduce screen time, improve quality of life, determine the perceptions towards the intervention, and validate the SB questionnaires. SB will be collected in the form of total daily SB, frequency of SB breaks, and duration of SB breaks. These variables will be measured through a SB and quality of life questionnaires that will be delivered through a downloadable mobile phone application. Outcome measures will be compared within and between groups to detect differences.


Recruitment information / eligibility

Status Recruiting
Enrollment 52
Est. completion date September 2023
Est. primary completion date September 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years or older - diagnosed with type 2 diabetes - access to a smart phone with internet connection - be able to read, write, and speak in english Exclusion Criteria: - any medical or physical limitation that would prevent standing, stretching, and/or light physical activity

Study Design


Intervention

Behavioral:
Health Action Process Approach (HAPA)
Health Action Process Approach (HAPA) using action planning and coping strategies to create health behaviour change

Locations

Country Name City State
Canada Harry Prapavessis London Ontario

Sponsors (1)

Lead Sponsor Collaborator
Western University

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Self-reported total sedentary behaviour Measured by the modified sedentary behaviour questionnaire (SBQ). Where total daily sedentary behaviour ranges from 0 to 24 hours. Higher number of hours is worse. Measured at week 0.
Primary Self-reported total sedentary behaviour Measured by the modified sedentary behaviour questionnaire (SBQ). Where total daily sedentary behaviour ranges from 0 to 24 hours. Higher number of hours is worse. Measured at week 2.
Primary Self-reported total sedentary behaviour Measured by the modified sedentary behaviour questionnaire (SBQ). Where total daily sedentary behaviour ranges from 0 to 24 hours. Higher number of hours is worse. Measured at week 4.
Primary Self-reported total sedentary behaviour Measured by the modified sedentary behaviour questionnaire (SBQ). Where total daily sedentary behaviour ranges from 0 to 24 hours. Higher number of hours is worse. Measured at week 6.
Primary Self-reported total sedentary behaviour Measured by the modified sedentary behaviour questionnaire (SBQ). Where total daily sedentary behaviour ranges from 0 to 24 hours. Higher number of hours is worse. Measured at week 12.
Primary Objectively measured total sedentary behaviour Measured by the ACTIVPAL4 Measured at week 0.
Primary Objectively measured total sedentary behaviour Measured by the ACTIVPAL4 Measured at week 6.
Primary Objectively measured total sedentary behaviour Measured by the ACTIVPAL4 Measured at week 12.
Secondary Self-reported sedentary behaviour break frequency Measured by the modified SIT-Q (no unabbreviated name) questionnaire. Where break frequency ranges from "less than every 30 minutes" to "over every 7 hours". Less frequent breaks is worse. Measured at week 0.
Secondary Self-reported sedentary behaviour break frequency Measured by the modified SIT-Q (no unabbreviated name) questionnaire. Where break frequency ranges from "less than every 30 minutes" to "over every 7 hours". Less frequent breaks is worse. Measured at week 2.
Secondary Self-reported sedentary behaviour break frequency Measured by the modified SIT-Q (no unabbreviated name) questionnaire. Where break frequency ranges from "less than every 30 minutes" to "over every 7 hours". Less frequent breaks is worse. Measured at week 4.
Secondary Self-reported sedentary behaviour break frequency Measured by the modified SIT-Q (no unabbreviated name) questionnaire. Where break frequency ranges from "less than every 30 minutes" to "over every 7 hours". Less frequent breaks is worse. Measured at week 6.
Secondary Self-reported sedentary behaviour break frequency Measured by the modified SIT-Q (no unabbreviated name) questionnaire. Where break frequency ranges from "less than every 30 minutes" to "over every 7 hours". Less frequent breaks is worse. Measured at week 12.
Secondary Self-reported sedentary behaviour break duration Measured by the modified SIT-Q (no unabbreviated name) questionnaire. Where break duration ranges from "less than 30 seconds" to "over every 30 minutes". Shorter breaks are worse. Measured at week 0.
Secondary Self-reported sedentary behaviour break duration Measured by the modified SIT-Q (no unabbreviated name) questionnaire. Where break duration ranges from "less than 30 seconds" to "over every 30 minutes". Shorter breaks are worse. Measured at week 2.
Secondary Self-reported sedentary behaviour break duration Measured by the modified SIT-Q (no unabbreviated name) questionnaire. Where break duration ranges from "less than 30 seconds" to "over every 30 minutes". Shorter breaks are worse. Measured at week 4.
Secondary Self-reported sedentary behaviour break duration Measured by the modified SIT-Q (no unabbreviated name) questionnaire. Where break duration ranges from "less than 30 seconds" to "over every 30 minutes". Shorter breaks are worse. Measured at week 6.
Secondary Self-reported sedentary behaviour break duration Measured by the modified SIT-Q (no unabbreviated name) questionnaire. Where break duration ranges from "less than 30 seconds" to "over every 30 minutes". Shorter breaks are worse. Measured at week 12.
Secondary Self-reported screen time Measured by a domain of the modified sedentary behaviour questionnaire (SBQ). Where total daily screen time ranges from 0 to 18 hours. Higher number of hours is worse. Measured at week 0.
Secondary Self-reported screen time Measured by a domain of the modified sedentary behaviour questionnaire (SBQ). Where total daily screen time ranges from 0 to 18 hours. Higher number of hours is worse. Measured at week 2.
Secondary Self-reported screen time Measured by a domain of the modified sedentary behaviour questionnaire (SBQ). Where total daily screen time ranges from 0 to 18 hours. Higher number of hours is worse. Measured at week 4.
Secondary Self-reported screen time Measured by a domain of the modified sedentary behaviour questionnaire (SBQ). Where total daily screen time ranges from 0 to 18 hours. Higher number of hours is worse. Measured at week 6.
Secondary Self-reported screen time Measured by a domain of the modified sedentary behaviour questionnaire (SBQ). Where total daily screen time ranges from 0 to 18 hours. Higher number of hours is worse. Measured at week 12.
Secondary Objective sedentary behaviour break frequency Measured by the ACTIVPAL4 Measured at week 0.
Secondary Objective sedentary behaviour break frequency Measured by the ACTIVPAL4 Measured at week 6.
Secondary Objective sedentary behaviour break frequency Measured by the ACTIVPAL4 Measured at week 12.
Secondary Objective sedentary behaviour break duration Measured by the ACTIVPAL4 Measured at week 0.
Secondary Objective sedentary behaviour break duration Measured by the ACTIVPAL4 Measured at week 6.
Secondary Objective sedentary behaviour break duration Measured by the ACTIVPAL4 Measured at week 12.
Secondary Self-reported quality of life Measured by the modified short form -36 (SF-36) questionnaire. This questionnaire will use sub-scales: role limitations due to physical health (4 yes/ no questions), role limitations due to emotional problems (6 yes/no questions), energy, fatigue, and emotional well-being (9 six-point scale questions). Measured at week 0.
Secondary Self-reported quality of life Measured by the modified short form -36 (SF-36) questionnaire. This questionnaire will use sub-scales: role limitations due to physical health (4 yes/ no questions), role limitations due to emotional problems (6 yes/no questions), energy, fatigue, and emotional well-being (9 six-point scale questions). Measured at week 6.
Secondary Self-reported quality of life Measured by the modified short form -36 (SF-36) questionnaire. This questionnaire will use sub-scales: role limitations due to physical health (4 yes/ no questions), role limitations due to emotional problems (6 yes/no questions), energy, fatigue, and emotional well-being (9 six-point scale questions). Measured at week 12.
Secondary Overall experience of the intervention The intervention group will receive at qualitative interview Measured at week 6.
Secondary Validate the modified sedentary behaviour questionnaire (SBQ) The modified sedentary behaviour (SBQ) will be validated with the ACTIVPAL4 Measured at week 0.
Secondary Validate the modified SIT-Q (no unabbreviated name) questionnaire The modified SIT-Q (no unabbreviated name) questionnaires will be validated with the ACTIVPAL4 Measured at week 0.
Secondary Validate the modified sedentary behaviour questionnaire (SBQ) The modified sedentary behaviour (SBQ) will be validated with the ACTIVPAL4 Measured at week 6.
Secondary Validate the modified SIT-Q (no unabbreviated name) questionnaire The modified SIT-Q (no unabbreviated name) questionnaire will be validated with the ACTIVPAL4 Measured at week 6.
Secondary Validate the modified sedentary behaviour questionnaire (SBQ) The modified sedentary behaviour questionnaire (SBQ) will be validated with the ACTIVPAL4 Measured at week 12.
Secondary Validate the modified SIT-Q (no unabbreviated name) questionnaire The modified SIT-Q (no unabbreviated name) questionnaires will be validated with the ACTIVPAL4 Measured at week 12.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2